Brii Biosciences announced full-year 2025 results, emphasizing progress in its hepatitis B treatments and a robust cash position of US$276.1 million. The Company’s Phase 2b HBV trials, ENRICH and ENHANCE, have fully enrolled and are poised for key data readouts in the second half of 2026.